“…For this reason, this grading system, although highly reproducible and useful for clinical decision making as to whether to initiate treatment, provides only limited information on the prognosis of patients. 10,11 Several clinical and biologic features have been identified as prognostically significant in previous studies of cGVHD, including categorization as extensive cGVHD, 9,12 Karnofsky performance status (KPS), 12 thrombocytopenia (o100 000 mm 3 ), 12,13 progressive-type onset of cGVHD, 14 lichenoid histology, 14 and elevated bilirubin. 14 According to recently introduced new clinical grading systems for cGVHD, 10,11 thrombocytopenia, progressive-type onset, and extensive skin GVHD, involving more than 50% of body surface area at the diagnosis of cGVHD, are independent risk factors affecting relapse-free survival.…”